AGP Executive Report
Last update: 33 minutes agoUS Pharma Tariffs, Liechtenstein in the Mix: The US Commerce Department has published a Federal Register list granting 0% ad valorem tariff treatment for select speciality medicines and related ingredients from 20 jurisdictions, including Liechtenstein, even as a broader 100% Section 232 tariff on certain patented drugs expands from 29 September. The zero-duty categories are narrowly defined (rare-disease drugs, infertility treatments, cell and gene therapies, antibody-drug conjugates, nuclear and plasma-derived medicines, plus certain medical countermeasures and animal pharmaceuticals), and eligibility depends on product qualification and applicable trade/security frameworks. EFTA Trade Check-In: India and EFTA (including Liechtenstein) will review the TEPA trade pact at an October summit in New Delhi, with officials pointing to declining Indian exports to the bloc and looking at market access and procedural bottlenecks. Market Watch: Europe’s upholstered furniture sector remains highly fragmented, with concentration slowly rising on the retail side and no single manufacturer holding even a 3% share—Cotta Collection (Liechtenstein) is named among the larger producers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Tariffs on patented drugs now apply to all branded drugmakers]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/28951606-946230721-6932eb68bfd3f6b08173c5b0da4ea8d6290db4f1-640x380-200x119.png)
![<![CDATA[New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report ]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/24259881-872312346-b2defa6b4904a34b5dfa8d86ebaaae1c7a81931b-1280x720-100x56.png)
